Exela Takes Alphagan Patent Ruling To Fed. Circ.

Law360, New York (November 20, 2009, 12:54 PM EST) -- Exela PharmSci Pvt. Ltd. wants a federal appeals court to review a decision that the Indian drugmaker's proposed generic version of Allergan Inc.’s glaucoma treatment Alphagan infringed a patent.

Exela PharmSci Pvt. And Exela Pharm Sci. Inc. filed a notice of appeal in the U.S. District Court for the District of Delaware on Thursday, saying they were appealing the trial court’s Oct. 23 order to the U.S. Court of Appeals for the Federal Circuit.

But Exela’s appeal isn’t just taking aim at that order. The Exela...
To view the full article, register now.